NDAORALTABLET
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
CALQUENCE (acalabrutinib) by AstraZeneca is tyrosine kinase inhibitors [moa]. Approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALQUENCE (acalabrutinib) is an oral tyrosine kinase inhibitor developed by AstraZeneca and approved by the FDA on August 3, 2022. It is indicated for the treatment of small lymphocytic lymphoma (SLL) and other hematologic malignancies including lymphoma and leukemia. The drug works by selectively inhibiting Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling, thereby inducing apoptosis in malignant B cells. CALQUENCE occupies a prominent position in the BTK inhibitor class, competing directly with other targeted kinase inhibitors in the hematology-oncology treatment landscape.
$1.3BPart D
10.2 years to LOEMechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on CALQUENCE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.